JP7653441B2 - Ｔ細胞アクティベーターとして有用な置換キノリノニルピペラジン化合物 - Google Patents
Ｔ細胞アクティベーターとして有用な置換キノリノニルピペラジン化合物 Download PDFInfo
- Publication number
- JP7653441B2 JP7653441B2 JP2022538818A JP2022538818A JP7653441B2 JP 7653441 B2 JP7653441 B2 JP 7653441B2 JP 2022538818 A JP2022538818 A JP 2022538818A JP 2022538818 A JP2022538818 A JP 2022538818A JP 7653441 B2 JP7653441 B2 JP 7653441B2
- Authority
- JP
- Japan
- Prior art keywords
- alkyl
- substituted
- cycloalkyl
- methyl
- compound
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/20—Oxygen atoms
- C07D215/22—Oxygen atoms attached in position 2 or 4
- C07D215/227—Oxygen atoms attached in position 2 or 4 only one oxygen atom which is attached in position 2
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Epidemiology (AREA)
- Virology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IN201911053557 | 2019-12-23 | ||
| IN201911053557 | 2019-12-23 | ||
| PCT/US2020/066503 WO2021133748A1 (en) | 2019-12-23 | 2020-12-22 | Substituted quinolinonyl piperazine compounds useful as t cell activators |
Publications (4)
| Publication Number | Publication Date |
|---|---|
| JP2023508055A JP2023508055A (ja) | 2023-02-28 |
| JPWO2021133748A5 JPWO2021133748A5 (https=) | 2023-12-07 |
| JP2023508055A5 JP2023508055A5 (https=) | 2023-12-07 |
| JP7653441B2 true JP7653441B2 (ja) | 2025-03-28 |
Family
ID=74195153
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022538818A Active JP7653441B2 (ja) | 2019-12-23 | 2020-12-22 | Ｔ細胞アクティベーターとして有用な置換キノリノニルピペラジン化合物 |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US20230061608A1 (https=) |
| EP (1) | EP4081513B1 (https=) |
| JP (1) | JP7653441B2 (https=) |
| KR (1) | KR20220119456A (https=) |
| CN (1) | CN115103841B (https=) |
| AU (1) | AU2020414688A1 (https=) |
| BR (1) | BR112022012220A2 (https=) |
| CA (1) | CA3162992A1 (https=) |
| ES (1) | ES2998500T3 (https=) |
| IL (1) | IL294269A (https=) |
| MX (1) | MX2022007369A (https=) |
| WO (1) | WO2021133748A1 (https=) |
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BR112022009631A2 (pt) * | 2019-12-19 | 2022-08-09 | Bristol Myers Squibb Co | Combinações de inibidores de dgk e antagonistas do ponto de checagem |
| LT4081305T (lt) | 2019-12-24 | 2024-11-25 | Carna Biosciences, Inc. | Diacilglicerolio kinazę moduliuojantys junginiai |
| WO2022271677A1 (en) | 2021-06-23 | 2022-12-29 | Gilead Sciences, Inc. | Diacylglyercol kinase modulating compounds |
| CA3222277A1 (en) | 2021-06-23 | 2022-12-29 | Gilead Sciences, Inc. | Diacylglyercol kinase modulating compounds |
| KR20240005901A (ko) | 2021-06-23 | 2024-01-12 | 길리애드 사이언시즈, 인코포레이티드 | 디아실글리세롤 키나제 조절 화합물 |
| WO2022271659A1 (en) | 2021-06-23 | 2022-12-29 | Gilead Sciences, Inc. | Diacylglyercol kinase modulating compounds |
| WO2023122772A1 (en) * | 2021-12-22 | 2023-06-29 | Gossamer Bio Services, Inc. | Oxime derivatives useful as t cell activators |
| WO2023122777A1 (en) * | 2021-12-22 | 2023-06-29 | Gossamer Bio Services, Inc. | Oxime derivatives useful as t cell activators |
| EP4472963A1 (en) * | 2022-02-01 | 2024-12-11 | Arvinas Operations, Inc. | Dgk targeting compounds and uses thereof |
| KR20240156394A (ko) | 2022-03-01 | 2024-10-29 | 인실리코 메디신 아이피 리미티드 | 디아실글리세롤 키나아제 (dgk) 알파 억제제 및 이의 용도 |
| CN115124464B (zh) * | 2022-07-04 | 2023-06-06 | 新乡学院 | 一种喹啉二酮磺酰哌嗪杂合体及其制备方法和应用 |
| US12600722B2 (en) | 2022-07-18 | 2026-04-14 | Incyte Corporation | Tetracyclic compounds as DGK inhibitors |
| US12600723B2 (en) | 2022-07-18 | 2026-04-14 | Incyte Corporation | Tetracyclic compounds as DGK inhibitors |
| AR131786A1 (es) | 2023-02-06 | 2025-04-30 | Bayer Ag | Combinación de anticuerpos ccr8 con inhibidores de dgk |
| WO2025030002A2 (en) * | 2023-08-02 | 2025-02-06 | Arvinas Operations, Inc. | Dgk targeting compounds and uses thereof |
| WO2025030163A1 (en) * | 2023-08-02 | 2025-02-06 | Horizon Therapeutics Ireland Dac | Heterocyclic inhibitors of igf-1r for treatment of disease |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2005500266A (ja) | 2001-05-24 | 2005-01-06 | アバニール・ファーマシューティカルズ | マクロファージ遊走阻止因子インヒビターおよびそれを同定する方法 |
| JP2006517977A (ja) | 2003-02-14 | 2006-08-03 | アバニール・ファーマシューティカルズ | マクロファージ遊走阻害因子の阻害剤およびそれらを同定するための方法 |
| WO2007114239A1 (ja) | 2006-03-30 | 2007-10-11 | Sapporo Medical University | DGKα阻害剤を含有する抗癌剤 |
| JP2009530384A (ja) | 2006-03-21 | 2009-08-27 | アヴァニール ファーマシューティカルズ | 腫瘍壊死因子アルファ阻害（抑制）剤及びそれらのヒトの病気処理における使用 |
Family Cites Families (34)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4284768A (en) * | 1980-07-02 | 1981-08-18 | American Home Products Corporation | 1,2-Dihydro-4-amino-2-oxo-3-quinoline-carboxylic acid derivatives |
| TWI309240B (en) | 2004-09-17 | 2009-05-01 | Hoffmann La Roche | Anti-ox40l antibodies |
| AU2006230099B2 (en) | 2005-03-25 | 2012-04-19 | Gitr, Inc. | GITR binding molecules and uses therefor |
| PL1879573T3 (pl) | 2005-05-10 | 2013-05-31 | Incyte Holdings Corp | Modulatory 2,3-dioksygenazy indoloaminy i sposoby ich zastosowania |
| CN104356236B (zh) | 2005-07-01 | 2020-07-03 | E.R.施贵宝&圣斯有限责任公司 | 抗程序性死亡配体1(pd-l1)的人单克隆抗体 |
| CA2634198C (en) | 2005-12-20 | 2014-06-03 | Incyte Corporation | N-hydroxyamidinoheterocycles as modulators of indoleamine 2,3-dioxygenase |
| CL2007002650A1 (es) | 2006-09-19 | 2008-02-08 | Incyte Corp | Compuestos derivados de heterociclo n-hidroxiamino; composicion farmaceutica, util para tratar cancer, infecciones virales y desordenes neurodegenerativos entre otras. |
| ES2444574T3 (es) | 2006-09-19 | 2014-02-25 | Incyte Corporation | N-hidroxiamidinoheterociclos como moduladores de la indolamina 2,3-dioxigenasa |
| EP1987839A1 (en) | 2007-04-30 | 2008-11-05 | I.N.S.E.R.M. Institut National de la Sante et de la Recherche Medicale | Cytotoxic anti-LAG-3 monoclonal antibody and its use in the treatment or prevention of organ transplant rejection and autoimmune disease |
| ES2776406T3 (es) | 2007-07-12 | 2020-07-30 | Gitr Inc | Terapias de combinación que emplean moléculas de enlazamiento a GITR |
| EP2044949A1 (en) | 2007-10-05 | 2009-04-08 | Immutep | Use of recombinant lag-3 or the derivatives thereof for eliciting monocyte immune response |
| JP5583592B2 (ja) | 2007-11-30 | 2014-09-03 | ニューリンク ジェネティクス コーポレイション | Ｉｄｏ阻害剤 |
| US20110176972A1 (en) | 2008-05-29 | 2011-07-21 | Saint-Gobain Centre De Recherches et D'Etudes Eur | Cellular structure containing aluminium titanate |
| AR072999A1 (es) | 2008-08-11 | 2010-10-06 | Medarex Inc | Anticuerpos humanos que se unen al gen 3 de activacion linfocitaria (lag-3) y los usos de estos |
| AU2009333580B2 (en) | 2008-12-09 | 2016-07-07 | Genentech, Inc. | Anti-PD-L1 antibodies and their use to enhance T-cell function |
| EP2473531A4 (en) | 2009-09-03 | 2013-05-01 | Merck Sharp & Dohme | Anti-gitr antibodies |
| US8722720B2 (en) | 2009-10-28 | 2014-05-13 | Newlink Genetics Corporation | Imidazole derivatives as IDO inhibitors |
| PH12012500881A1 (en) | 2009-12-10 | 2017-07-26 | Hoffmann La Roche | Antibodies binding preferentially human csf1r extracellular domain 4 and their use |
| JP5998060B2 (ja) | 2010-03-04 | 2016-09-28 | マクロジェニクス，インコーポレーテッド | Ｂ７−ｈ３と反応性のある抗体、その免疫学的に活性なフラグメントおよびその使用 |
| CA2789076C (en) | 2010-03-05 | 2017-11-21 | F. Hoffmann-La Roche Ag | Antibodies against human colony stimulating factor-1 receptor and uses thereof |
| CN102918061B (zh) | 2010-03-05 | 2016-06-08 | 霍夫曼-拉罗奇有限公司 | 针对人csf-1r的抗体及其用途 |
| MX378336B (es) | 2010-05-04 | 2025-03-10 | Five Prime Therapeutics Inc | Anticuerpos que se unen a factor estimulante de colonias 1 (csf1r). |
| PT2614082T (pt) | 2010-09-09 | 2018-12-03 | Pfizer | Moléculas de ligação a 4-1bb |
| NO2694640T3 (https=) | 2011-04-15 | 2018-03-17 | ||
| KR101970025B1 (ko) | 2011-04-20 | 2019-04-17 | 메디뮨 엘엘씨 | Ｂ7-ｈ1 및 ｐｄ-1과 결합하는 항체 및 다른 분자들 |
| HRP20201595T1 (hr) | 2011-11-28 | 2020-12-11 | Merck Patent Gmbh | Anti-pd-l1 protutijela i njihova uporaba |
| BR112014012624A2 (pt) | 2011-12-15 | 2018-10-09 | F Hoffmann-La Roche Ag | anticorpos, composição farmacêutica, ácido nucleico, vetores de expressão, célula hospedeira, método para a produção de um anticorpo recombinante e uso do anticorpo |
| RU2014136332A (ru) | 2012-02-06 | 2016-03-27 | Дженентек, Инк. | Композиции и способы применения ингибиторов csf1r |
| AR090263A1 (es) | 2012-03-08 | 2014-10-29 | Hoffmann La Roche | Terapia combinada de anticuerpos contra el csf-1r humano y las utilizaciones de la misma |
| EP2847220A1 (en) | 2012-05-11 | 2015-03-18 | Five Prime Therapeutics, Inc. | Methods of treating conditions with antibodies that bind colony stimulating factor 1 receptor (csf1r) |
| AR091649A1 (es) | 2012-07-02 | 2015-02-18 | Bristol Myers Squibb Co | Optimizacion de anticuerpos que se fijan al gen de activacion de linfocitos 3 (lag-3) y sus usos |
| CN107759690A (zh) | 2012-08-31 | 2018-03-06 | 戊瑞治疗有限公司 | 用结合群落刺激因子1受体(csf1r)的抗体治疗病状的方法 |
| JP6464139B2 (ja) * | 2013-03-14 | 2019-02-06 | コンバージーン・リミテッド・ライアビリティ・カンパニーＣｏｎｖｅｒｇｅｎｅ Ｌｌｃ | ブロモドメイン含有タンパク質の阻害のための方法および組成物 |
| CN112654621B (zh) * | 2018-06-27 | 2024-05-14 | 百时美施贵宝公司 | 可作为t细胞活化剂的经取代萘啶酮化合物 |
-
2020
- 2020-12-22 KR KR1020227025288A patent/KR20220119456A/ko active Pending
- 2020-12-22 CN CN202080096443.9A patent/CN115103841B/zh active Active
- 2020-12-22 AU AU2020414688A patent/AU2020414688A1/en not_active Abandoned
- 2020-12-22 MX MX2022007369A patent/MX2022007369A/es unknown
- 2020-12-22 WO PCT/US2020/066503 patent/WO2021133748A1/en not_active Ceased
- 2020-12-22 IL IL294269A patent/IL294269A/en unknown
- 2020-12-22 JP JP2022538818A patent/JP7653441B2/ja active Active
- 2020-12-22 CA CA3162992A patent/CA3162992A1/en active Pending
- 2020-12-22 EP EP20845303.5A patent/EP4081513B1/en active Active
- 2020-12-22 ES ES20845303T patent/ES2998500T3/es active Active
- 2020-12-22 US US17/786,239 patent/US20230061608A1/en active Pending
- 2020-12-22 BR BR112022012220A patent/BR112022012220A2/pt not_active IP Right Cessation
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2005500266A (ja) | 2001-05-24 | 2005-01-06 | アバニール・ファーマシューティカルズ | マクロファージ遊走阻止因子インヒビターおよびそれを同定する方法 |
| JP2006517977A (ja) | 2003-02-14 | 2006-08-03 | アバニール・ファーマシューティカルズ | マクロファージ遊走阻害因子の阻害剤およびそれらを同定するための方法 |
| JP2009530384A (ja) | 2006-03-21 | 2009-08-27 | アヴァニール ファーマシューティカルズ | 腫瘍壊死因子アルファ阻害（抑制）剤及びそれらのヒトの病気処理における使用 |
| WO2007114239A1 (ja) | 2006-03-30 | 2007-10-11 | Sapporo Medical University | DGKα阻害剤を含有する抗癌剤 |
Also Published As
| Publication number | Publication date |
|---|---|
| AU2020414688A1 (en) | 2022-08-18 |
| MX2022007369A (es) | 2022-07-12 |
| BR112022012220A2 (pt) | 2022-09-13 |
| EP4081513A1 (en) | 2022-11-02 |
| CA3162992A1 (en) | 2021-07-01 |
| WO2021133748A1 (en) | 2021-07-01 |
| ES2998500T3 (en) | 2025-02-20 |
| CN115103841A (zh) | 2022-09-23 |
| JP2023508055A (ja) | 2023-02-28 |
| CN115103841B (zh) | 2024-12-27 |
| EP4081513B1 (en) | 2024-11-20 |
| KR20220119456A (ko) | 2022-08-29 |
| US20230061608A1 (en) | 2023-03-02 |
| IL294269A (en) | 2022-08-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP7653441B2 (ja) | Ｔ細胞アクティベーターとして有用な置換キノリノニルピペラジン化合物 | |
| JP7677976B2 (ja) | Ｔ細胞アクティベーターとして有用な置換ヘテロアリール化合物 | |
| TWI836159B (zh) | 可作為helios蛋白質抑制劑之化合物 | |
| CN114846007B (zh) | 可用作t细胞激活剂的经取代的喹唑啉基化合物 | |
| JP7712274B2 (ja) | Ｔ細胞アクティベーターとして有用な置換ピペラジン誘導体 | |
| KR102804324B1 (ko) | T 세포 활성화제로서 유용한 나프티리디논 화합물 | |
| JP7821197B2 (ja) | ピリジニル置換されたオキソイソインドリン化合物 | |
| JP2026501039A (ja) | 置換フェニルオキサゾロン化合物 | |
| JP2025528134A (ja) | Ｔ細胞活性化剤として有用な置換テトラゾリル化合物 | |
| JP2025528157A (ja) | Ｔ細胞活性化剤として有用な第三アミン置換二環式化合物 | |
| EA047609B1 (ru) | Замещенные гетероарильные соединения, полезные в качестве активаторов т-клеток |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20231129 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20231129 |
|
| A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20241024 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20241105 |
|
| RD04 | Notification of resignation of power of attorney |
Free format text: JAPANESE INTERMEDIATE CODE: A7424 Effective date: 20241115 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20241121 |
|
| TRDD | Decision of grant or rejection written | ||
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20250218 |
|
| A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20250317 |
|
| R150 | Certificate of patent or registration of utility model |
Ref document number: 7653441 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |